€¦ · web view* library staff make every effort to provide accurate and complete database...

* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

Supplementary material – best viewed in Microsoft Word in “Web Layout”

Appendix 1 – Literature search strategy

UHN Health Sciences Libraries

Literature Search Results

For: Eitan Amir

Department: Medical Oncology & Hematology

Date Completed: June 16, 2014

Tel:

Fax:

Attached is your search for:

Phase 3 and phase 4 clinical trials on angiogenesis inhibitors in cancer treatment, limited to 1990- current, and humans.

The databases searched were:

Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <June 13, 2014>

SEARCH STRATEGY: See below

SEARCH RESULTS: See attached

Search Completed By: Junhui Zhang

Information Specialist

416-946-6539

[email protected]


mailto:[email protected]

It is important that you are satisfied with your search results.If you have any questions regarding this search, or if the results were not satisfactory, please do not hesitate in contacting me.

To request items not available in our library system, an INTERLIBRARY LOAN REQUEST FORM can be obtained from the library’s circulation desk or through the Virtual Library. Any questions regarding our Document Delivery Service can be directed to Walter by telephone at 416-340-4121 or by email at [email protected].

For any other circulation inquiries:

Toronto General Hospital Library: (416) 340-3429Toronto Western Hospital Library: (416) 603-5750Toronto Rehab Library: (416) 597-3422, ext. 3050Princess Margaret Library: (416) 946-4482



Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <June 13, 2014>Search Strategy: --------------------------------------------------------------------------------1 neoplasm*.hw. (15)2 exp Neoplasms/ (16)3 cancer*.mp. (81371)4 tumor*.mp. (58548)5 tumour*.mp. (11841)6 carcin*.mp. (32466)7 neoplas*.mp. (12909)8 lymphoma*.mp. (6395)9 melanoma*.mp. (4246)10 melanotic*.mp. (125)11 metasta*.mp. (25450)12 non small cell.mp. (3282)13 nonsmall cell.mp. (172)14 (nonsmall adj2 cell).mp. (172)15 nsclc.mp. (2286)16 adenocarcin*.mp. (6268)17 osteosarcom*.mp. (974)18 phyllodes.mp. (96)19 cystosarcom*.mp. (17)20 fibroadenom*.mp. (162)21 hepatoma*.mp. (701)22 hepatoblastom*.mp. (125)23 plasmacytoma*.mp. (209)24 myeloma?.mp. (1895)25 blastoma*.mp. (42)


26 lymphangioma*.mp. (267)27 lymphangiomyoma*.mp. (13)28 lymphangiosarcoma*.mp. (11)29 lymphoblastoma*.mp. (11)30 lymphocytoma*.mp. (11)31 lymphosarcoma*.mp. (90)32 lymphoma?.mp. (6304)33 immunocytoma?.mp. (1)34 angiosarcoma*.mp. (287)35 malignan*.mp. (24844)36 astrocytoma*.mp. (553)37 neuroma?.mp. (332)38 cytoma?.mp. (1)39 gist.mp. (503)40 neurocytoma?.mp. (35)41 oncolog*.mp. (7533)42 exp Medical Oncology/ (0)43 exp Radiation Oncology/ (0)44 neoplasm staging/ (0)45 staging.mp. (3537)46 squamous cell?.mp. (4992)47 cytosarcoma*.mp. (0)48 sarcoma*.mp. (4354)49 hodgkin*.mp. (2115)50 non-hodgkin*.mp. (1359)51 nonhodgkin*.mp. (8)52 incidentaloma?.mp. (145)53 retinoblastoma?.mp. (488)54 plasmacytoma*.mp. (209)55 cholangiocarcinoma*.mp. (715)56 leiomyoblastoma*.mp. (3)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

57 leiomyocarcinoma*.mp. (0)58 leiomyosarcoma*.mp. (410)59 sc.fs. ["secondary" floating subheading] (1)60 melanosis.mp. (95)61 (hutchinson* adj2 freckle*).mp. (0)62 melanoameloblastom*.mp. (0)63 melanoblastom*.mp. (2)64 melanocarcin*.mp. (1)65 melanomalign*.mp. (0)66 naevocarcin*.mp. (2)67 nevocarcin*.mp. (0)68 adamantinom*.mp. (41)69 ameloblastom*.mp. (237)70 adenosquam*.mp. (128)71 teratoma*.mp. (744)72 leukemia*.mp. (6546)73 metaplas*.mp. (765)74 or/1-73 (159596)75 exp Angiogenesis Inhibitors/ (0)76 exp Neovascularization, Pathologic/ (0)77 limit 76 to yr="1990 - 1999" (0)78 exp Protein Kinase Inhibitors/ (0)79 exp Protein Kinases/ (3)80 limit 79 to yr="1990 - 2004" (0)81 exp Vascular Endothelial Growth Factors/ (0)82 exp Endothelial Growth Factors/ (0)83 limit 82 to yr="1990 - 2003" (0)84 bevacizumab.mp. (1124)85 altuzan?.mp. (0)86 avastin?.mp. (125)87 nsc 704865.mp. (0)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

88 nsc704865.mp. (0)89 216974-75-3.rn. (0)90 aflibercept.mp. (62)91 "ave 0005".mp. (0)92 ave0005.mp. (0)93 eylea?.mp. (4)94 zaltrap?.mp. (2)95 845771-78-0.rn. (0)96 862111-32-8.rn. (0)97 ramucirumab.mp. (18)98 cyramza?.mp. (0)99 imc 1121 b.mp. (0)100 imc 1121b.mp. (3)101 imc1121b.mp. (0)102 ly 3009806.mp. (0)103 ly3009806.mp. (0)104 947687-13-0.rn. (0)105 sunitinib.mp. (456)106 pha 2909040ad.mp. (0)107 pha2909040ad.mp. (0)108 "su 010398".mp. (0)109 "su 011248".mp. (0)110 su 10398.mp. (0)111 su 11248.mp. (0)112 su010398.mp. (0)113 su011248.mp. (0)114 su10398.mp. (0)115 su11248.mp. (4)116 suo 11248.mp. (0)117 sutent?.mp. (14)118 suo11248.mp. (1)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

119 sorafenib.mp. (595)120 bay 43 9006.mp. (6)121 bay 439006.mp. (0)122 bay43 9006.mp. (2)123 bay439006.mp. (0)124 nexavar?.mp. (17)125 284461-73-0.rn. (0)126 pazopanib.mp. (116)127 armala?.mp. (0)128 gw 786034.mp. (0)129 gw 786034b.mp. (0)130 gw 786034x.mp. (0)131 gw786034.mp. (2)132 gw786034b.mp. (0)133 gw786034x.mp. (0)134 sb 710468.mp. (0)135 sb 710468a.mp. (0)136 sb710468.mp. (0)137 sb710468a.mp. (0)138 votrient?.mp. (2)139 444731-52-6.rn. (0)140 635702-64-6.rn. (0)141 vandetanib.mp. (56)142 azd 6474.mp. (0)143 azd6474.mp. (0)144 caprelsa?.mp. (3)145 vandetinib.mp. (0)146 zactima?.mp. (4)147 zd 6474.mp. (2)148 zd6474.mp. (13)149 338992-00-0.rn. (0)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

150 338992-48-6.rn. (0)151 443913-73-3.rn. (0)152 cabozantinib.mp. (35)153 bms 907351.mp. (0)154 bms907351.mp. (0)155 cometriq?.mp. (1)156 xl 184.mp. (0)157 xl184.mp. (3)158 1140909-48-3.rn. (0)159 849217-68-1.rn. (0)160 942407-59-2.rn. (0)161 axitinib.mp. (61)162 "ag 013736".mp. (2)163 ag 13736.mp. (0)164 ag013736.mp. (0)165 ag13736.mp. (0)166 inlyta?.mp. (3)167 319460-85-0.rn. (0)168 ponatinib.mp. (41)169 ap 24534.mp. (0)170 ap24534.mp. (5)171 iclusig?.mp. (6)172 1114544-31-8.rn. (0)173 943319-70-8.rn. (0)174 regorafenib.mp. (39)175 bay 73 4506.mp. (3)176 bay 73-4506.mp. (3)177 bay 734506.mp. (0)178 bay73 4506.mp. (0)179 bay734506.mp. (0)180 stivarga?.mp. (4)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

181 1019206-88-2.rn. (0)182 755037-03-7.rn. (0)183 everolimus.mp. (433)184 affinitor?.mp. (0)185 afinitor?.mp. (8)186 certican?.mp. (2)187 "nvp rad 001".mp. (0)188 nvp rad001.mp. (0)189 "rad 001".mp. (4)190 rad 001a.mp. (0)191 rad001.mp. (33)192 rad001a.mp. (0)193 sdz rad.mp. (1)194 votubia?.mp. (0)195 xience?.mp. (33)196 zortress?.mp. (1)197 159351-69-6.rn. (0)198 temsirolimus.mp. (124)199 cci 779.mp. (6)200 cci779.mp. (0)201 nsc 683864.mp. (0)202 nsc683864.mp. (0)203 rapamycin 2.mp. (5)204 rapamycin 42.mp. (0)205 torisel?.mp. (0)206 162635-04-3.mp. (0)207 343261-52-9.mp. (0)208 75 or 77 or 78 or 80 or 81 or 83 (0)209 or/84-207 (2634)210 208 or 209 (2634)211 clinical trial, phase iii/ (11)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

212 Clinical Trials, Phase III as Topic/ (0)213 (phase adj3 three).mp. (1234)214 (phase adj3 iii).mp. (2218)215 (phase adj3 "3").mp. (1430)216 phase3.mp. (0)217 phaseiii.mp. (2)218 clinical trial, phase iv/ (0)219 CLINICAL TRIALS, PHASE IV AS TOPIC/ (0)220 (phase adj3 "4").mp. (545)221 (phase adj3 four).mp. (427)222 (phase adj3 iv).mp. (225)223 (phase adj3 "2/3").mp. (36)224 (phase adj3 "3/4").mp. (11)225 (phase adj3 "ii/iii").mp. (84)226 (phase adj3 "iii/iv").mp. (8)227 (phase adj3 "two/three").mp. (2)228 (phase adj3 "three/four").mp. (0)229 or/211-228 (5740)230 exp Clinical Trial/ (645)231 limit 230 to yr="1990 - 1992" (24)232 exp clinical trial as topic/ (5)233 limit 232 to yr="1990 - 1992" (0)234 229 or 231 or 233 (5764)235 74 and 210 and 234 (205)236 Animals/ (27)237 Humans/ (84)238 236 not (236 and 237) (5)239 235 not 238 (205)240 limit 239 to yr="1990 -Current" (205)241 remove duplicates from 240 (205)


***************************



For: Eitan Amir



Tel:

Fax:




Ovid MEDLINE(R) <1946 to June Week 1 2014>






416-946-6539

[email protected]








Database: Ovid MEDLINE(R) <1946 to June Week 1 2014>Search Strategy:

Cancer terms

1 neoplasm*.hw. (2094982)2 exp Neoplasms/ (2557667)3 cancer*.mp. (1033919)4 tumor*.mp. (1275577)5 tumour*.mp. (196072)6 carcin*.mp. (730453)7 neoplas*.mp. (2170332)8 lymphoma*.mp. (179998)9 melanoma*.mp. (91996)10 melanotic*.mp. (2442)11 metasta*.mp. (355446)12 non small cell.mp. (37531)13 nonsmall cell.mp. (1730)14 (nonsmall adj2 cell).mp. (1732)15 nsclc.mp. (17262)16 adenocarcin*.mp. (173579)17 osteosarcom*.mp. (21464)18 phyllodes.mp. (1723)19 cystosarcom*.mp. (595)20 fibroadenom*.mp. (3485)21 hepatoma*.mp. (24030)22 hepatoblastom*.mp. (2792)23 plasmacytoma*.mp. (9091)24 myeloma?.mp. (44270)25 blastoma*.mp. (972)26 lymphangioma*.mp. (5783)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

27 lymphangiomyoma*.mp. (476)28 lymphangiosarcoma*.mp. (391)29 lymphoblastoma*.mp. (267)30 lymphocytoma*.mp. (265)31 lymphosarcoma*.mp. (4483)32 lymphoma?.mp. (178298)33 immunocytoma?.mp. (485)34 angiosarcoma*.mp. (4336)35 malignan*.mp. (385582)36 astrocytoma*.mp. (17824)37 neuroma?.mp. (9647)38 cytoma?.mp. (40)39 gist.mp. (3594)40 neurocytoma?.mp. (632)41 oncolog*.mp. (86600)42 exp Medical Oncology/ (14728)43 exp Radiation Oncology/ (2634)44 neoplasm staging/ (121693)45 staging.mp. (147558)46 squamous cell?.mp. (120115)47 cytosarcoma*.mp. (10)48 sarcoma*.mp. (94748)49 hodgkin*.mp. (74925)50 non-hodgkin*.mp. (45093)51 nonhodgkin*.mp. (102)52 incidentaloma?.mp. (1223)53 retinoblastoma?.mp. (18120)54 plasmacytoma*.mp. (9091)55 cholangiocarcinoma*.mp. (7617)56 leiomyoblastoma*.mp. (388)57 leiomyocarcinoma*.mp. (1)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

58 leiomyosarcoma*.mp. (9493)59 sc.fs. ["secondary" floating subheading] (124620)60 melanosis.mp. (3300)61 (hutchinson* adj2 freckle*).mp. (494)62 melanoameloblastom*.mp. (10)63 melanoblastom*.mp. (445)64 melanocarcin*.mp. (92)65 melanomalign*.mp. (44)66 naevocarcin*.mp. (31)67 nevocarcin*.mp. (66)68 adamantinom*.mp. (708)69 ameloblastom*.mp. (3299)70 adenosquam*.mp. (2720)71 teratoma*.mp. (17833)72 leukemia*.mp. (248050)73 metaplas*.mp. (19499)74 or/1-73 (3210786)

Angiogenesis inhibitors terms (included related MeSHs and specific drug terms identified by researchers)75 exp Angiogenesis Inhibitors/ (34150)76 exp Neovascularization, Pathologic/ (38104)77 limit 76 to yr="1990 - 1999" (5790)78 exp Protein Kinase Inhibitors/ (45804)79 exp Protein Kinases/ (369075)80 limit 79 to yr="1990 - 2004" (142811)81 exp Vascular Endothelial Growth Factors/ (36869)82 exp Endothelial Growth Factors/ (7984)83 limit 82 to yr="1990 - 2003" (7721)84 bevacizumab.mp. (8253)85 altuzan?.mp. (0)


86 avastin?.mp. (937)87 nsc 704865.mp. (0)88 nsc704865.mp. (0)89 216974-75-3.rn. (0)90 aflibercept.mp. (264)91 "ave 0005".mp. (1)92 ave0005.mp. (2)93 eylea?.mp. (9)94 zaltrap?.mp. (8)95 845771-78-0.rn. (0)96 862111-32-8.rn. (0)97 ramucirumab.mp. (29)98 cyramza?.mp. (0)99 imc 1121 b.mp. (0)100 imc 1121b.mp. (7)101 imc1121b.mp. (0)102 ly 3009806.mp. (0)103 ly3009806.mp. (0)104 947687-13-0.rn. (0)105 sunitinib.mp. (2845)106 pha 2909040ad.mp. (0)107 pha2909040ad.mp. (0)108 "su 010398".mp. (0)109 "su 011248".mp. (2)110 su 10398.mp. (0)111 su 11248.mp. (20)112 su010398.mp. (0)113 su011248.mp. (6)114 su10398.mp. (0)115 su11248.mp. (114)116 suo 11248.mp. (1)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

117 sutent?.mp. (104)118 suo11248.mp. (0)119 sorafenib.mp. (3390)120 bay 43 9006.mp. (122)121 bay 439006.mp. (0)122 bay43 9006.mp. (28)123 bay439006.mp. (0)124 nexavar?.mp. (98)125 284461-73-0.rn. (0)126 pazopanib.mp. (431)127 armala?.mp. (1)128 gw 786034.mp. (4)129 gw 786034b.mp. (0)130 gw 786034x.mp. (0)131 gw786034.mp. (17)132 gw786034b.mp. (2)133 gw786034x.mp. (0)134 sb 710468.mp. (0)135 sb 710468a.mp. (0)136 sb710468.mp. (0)137 sb710468a.mp. (0)138 votrient?.mp. (12)139 444731-52-6.rn. (0)140 635702-64-6.rn. (0)141 vandetanib.mp. (298)142 azd 6474.mp. (0)143 azd6474.mp. (0)144 caprelsa?.mp. (8)145 vandetinib.mp. (2)146 zactima?.mp. (35)147 zd 6474.mp. (8)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

148 zd6474.mp. (164)149 338992-00-0.rn. (0)150 338992-48-6.rn. (0)151 443913-73-3.rn. (0)152 cabozantinib.mp. (75)153 bms 907351.mp. (1)154 bms907351.mp. (0)155 cometriq?.mp. (0)156 xl 184.mp. (13)157 xl184.mp. (29)158 1140909-48-3.rn. (0)159 849217-68-1.rn. (0)160 942407-59-2.rn. (0)161 axitinib.mp. (268)162 "ag 013736".mp. (37)163 ag 13736.mp. (1)164 ag013736.mp. (8)165 ag13736.mp. (1)166 inlyta?.mp. (3)167 319460-85-0.rn. (0)168 ponatinib.mp. (96)169 ap 24534.mp. (1)170 ap24534.mp. (22)171 iclusig?.mp. (0)172 1114544-31-8.rn. (0)173 943319-70-8.rn. (0)174 regorafenib.mp. (70)175 bay 73 4506.mp. (7)176 bay 73-4506.mp. (7)177 bay 734506.mp. (0)178 bay73 4506.mp. (0)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

179 bay734506.mp. (0)180 stivarga?.mp. (4)181 1019206-88-2.rn. (0)182 755037-03-7.rn. (0)183 everolimus.mp. (2615)184 affinitor?.mp. (0)185 afinitor?.mp. (16)186 certican?.mp. (62)187 "nvp rad 001".mp. (0)188 nvp rad001.mp. (0)189 "rad 001".mp. (44)190 rad 001a.mp. (0)191 rad001.mp. (326)192 rad001a.mp. (0)193 sdz rad.mp. (65)194 votubia?.mp. (0)195 xience?.mp. (173)196 zortress?.mp. (2)197 159351-69-6.rn. (2013)198 temsirolimus.mp. (876)199 cci 779.mp. (168)200 cci779.mp. (2)201 nsc 683864.mp. (7)202 nsc683864.mp. (0)203 rapamycin 2.mp. (42)204 rapamycin 42.mp. (1)205 torisel?.mp. (20)206 162635-04-3.mp. (0)207 343261-52-9.mp. (0)208 75 or 77 or 78 or 80 or 81 or 83 (248571)209 or/84-207 (16534)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

210 208 or 209 (256930)

Phase 3 phase 4 terms

211 clinical trial, phase iii/ (9030)212 Clinical Trials, Phase III as Topic/ (6348)213 (phase adj3 three).mp. (5426)214 (phase adj3 iii).mp. (30430)215 (phase adj3 "3").mp. (9899)216 phase3.mp. (13)217 phaseiii.mp. (4)218 clinical trial, phase iv/ (936)219 CLINICAL TRIALS, PHASE IV AS TOPIC/ (224)220 (phase adj3 "4").mp. (4098)221 (phase adj3 four).mp. (1836)222 (phase adj3 iv).mp. (2449)223 (phase adj3 "2/3").mp. (289)224 (phase adj3 "3/4").mp. (145)225 (phase adj3 "ii/iii").mp. (942)226 (phase adj3 "iii/iv").mp. (54)227 (phase adj3 "two/three").mp. (11)228 (phase adj3 "three/four").mp. (2)229 or/211-228 (49450)230 exp Clinical Trial/ (769122)231 limit 230 to yr="1990 - 1992" (36246)232 exp clinical trial as topic/ (281329)233 limit 232 to yr="1990 - 1992" (8145)234 229 or 231 or 233 (88944)

Combined results

235 74 and 210 and 234 (2668)236 Animals/ (5325729)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

237 Humans/ (13489675)238 236 not (236 and 237) (3858253)239 235 not 238 (2641)240 limit 239 to yr="1990 -Current" (2641)241 remove duplicates from 240 (2514)

***************************

127 duplicates



For: Eitan Amir



Tel:

Fax:




Ovid Embase <1974 to 2014 June 13>






416-946-6539

[email protected]








Database: Embase <1974 to 2014 June 13>Search Strategy:

Cancer terms

1 neoplasm*.hw. (352187)2 exp Neoplasms/ (3382146)3 cancer*.mp. (2186342)4 tumor*.mp. (2066138)5 tumour*.mp. (259863)6 carcin*.mp. (1073454)7 neoplas*.mp. (649641)8 lymphoma*.mp. (224674)9 melanoma*.mp. (131706)10 melanotic*.mp. (2350)11 metasta*.mp. (536778)12 non small cell.mp. (66074)13 nonsmall cell.mp. (3001)14 (nonsmall adj2 cell).mp. (3002)15 nsclc.mp. (33175)16 adenocarcin*.mp. (177888)17 osteosarcom*.mp. (29625)18 phyllodes.mp. (1681)19 cystosarcom*.mp. (2104)20 fibroadenom*.mp. (5271)21 hepatoma*.mp. (30332)22 hepatoblastom*.mp. (4192)23 plasmacytoma*.mp. (10233)24 myeloma?.mp. (67680)25 blastoma*.mp. (2290)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

26 lymphangioma*.mp. (8018)27 lymphangiomyoma*.mp. (553)28 lymphangiosarcoma*.mp. (482)29 lymphoblastoma*.mp. (2290)30 lymphocytoma*.mp. (2522)31 lymphosarcoma*.mp. (6158)32 lymphoma?.mp. (221537)33 immunocytoma?.mp. (654)34 angiosarcoma*.mp. (8906)35 malignan*.mp. (558828)36 astrocytoma*.mp. (23892)37 neuroma?.mp. (9225)38 cytoma?.mp. (87)39 gist.mp. (6968)40 neurocytoma?.mp. (758)41 oncolog*.mp. (210699)42 exp Medical Oncology/ (96520)43 exp Radiation Oncology/ (96520)44 neoplasm staging/ (169303)45 staging.mp. (212097)46 squamous cell?.mp. (137682)47 cytosarcoma*.mp. (29)48 sarcoma*.mp. (120585)49 hodgkin*.mp. (84477)50 non-hodgkin*.mp. (40097)51 nonhodgkin*.mp. (48382)52 incidentaloma?.mp. (2227)53 retinoblastoma?.mp. (22186)54 plasmacytoma*.mp. (10233)55 cholangiocarcinoma*.mp. (10274)56 leiomyoblastoma*.mp. (606)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

57 leiomyocarcinoma*.mp. (0)58 leiomyosarcoma*.mp. (13035)59 sc.fs. ["secondary" floating subheading] (105471)60 melanosis.mp. (3594)61 (hutchinson* adj2 freckle*).mp. (76)62 melanoameloblastom*.mp. (84)63 melanoblastom*.mp. (487)64 melanocarcin*.mp. (97)65 melanomalign*.mp. (46)66 naevocarcin*.mp. (38)67 nevocarcin*.mp. (66)68 adamantinom*.mp. (773)69 ameloblastom*.mp. (4227)70 adenosquam*.mp. (5947)71 teratoma*.mp. (27283)72 leukemia*.mp. (341786)73 metaplas*.mp. (28868)74 or/1-73 (4316739)

Angiogenesis inhibitors terms (included related MeSHs and specific drug terms identified by researchers)75 exp angiogenesis inhibitor/ (81165)76 exp Protein Kinase Inhibitors/ (239179)77 vasculotropin/ (65080)78 bevacizumab.mp. (32128)79 altuzan?.mp. (12)80 avastin?.mp. (7621)81 nsc 704865.mp. (5)82 nsc704865.mp. (0)83 216974-75-3.rn. (26632)84 aflibercept.mp. (1593)


85 "ave 0005".mp. (65)86 ave0005.mp. (6)87 eylea?.mp. (126)88 zaltrap?.mp. (84)89 845771-78-0.rn. (1403)90 862111-32-8.rn. (1403)91 ramucirumab/ (351)92 ramucirumab.mp. (357)93 cyramza?.mp. (0)94 imc 1121 b.mp. (18)95 imc 1121b.mp. (176)96 imc1121b.mp. (1)97 ly 3009806.mp. (3)98 ly3009806.mp. (0)99 947687-13-0.rn. (322)100 sunitinib.mp. (13309)101 pha 2909040ad.mp. (0)102 pha2909040ad.mp. (0)103 "su 010398".mp. (2)104 "su 011248".mp. (146)105 su 10398.mp. (0)106 su 11248.mp. (1241)107 su010398.mp. (0)108 su011248.mp. (21)109 su10398.mp. (0)110 su11248.mp. (204)111 suo 11248.mp. (6)112 sutent?.mp. (2163)113 suo11248.mp. (2)114 sorafenib.mp. (15623)115 bay 43 9006.mp. (1018)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

116 bay 439006.mp. (557)117 bay43 9006.mp. (51)118 bay439006.mp. (6)119 nexavar?.mp. (2129)120 284461-73-0.rn. (12220)121 pazopanib.mp. (3014)122 armala?.mp. (11)123 gw 786034.mp. (342)124 gw 786034b.mp. (15)125 gw 786034x.mp. (0)126 gw786034.mp. (46)127 gw786034b.mp. (5)128 gw786034x.mp. (0)129 sb 710468.mp. (0)130 sb 710468a.mp. (0)131 sb710468.mp. (0)132 sb710468a.mp. (0)133 votrient?.mp. (335)134 444731-52-6.rn. (2526)135 635702-64-6.rn. (2526)136 vandetanib.mp. (3040)137 azd 6474.mp. (44)138 azd6474.mp. (0)139 caprelsa?.mp. (116)140 vandetinib.mp. (10)141 zactima?.mp. (478)142 zd 6474.mp. (1261)143 zd6474.mp. (268)144 338992-00-0.rn. (2780)145 338992-48-6.rn. (2780)146 443913-73-3.rn. (2780)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

147 cabozantinib.mp. (644)148 bms 907351.mp. (28)149 bms907351.mp. (0)150 cometriq?.mp. (42)151 xl 184.mp. (425)152 xl184.mp. (117)153 1140909-48-3.rn. (518)154 849217-68-1.rn. (518)155 942407-59-2.rn. (710)156 axitinib.mp. (1991)157 "ag 013736".mp. (566)158 ag 13736.mp. (25)159 ag013736.mp. (26)160 ag13736.mp. (2)161 inlyta?.mp. (100)162 319460-85-0.rn. (1742)163 ponatinib/ (550)164 ponatinib.mp. (564)165 ap 24534.mp. (152)166 ap24534.mp. (70)167 iclusig?.mp. (45)168 1114544-31-8.rn. (357)169 943319-70-8.rn. (404)170 regorafenib.mp. (533)171 bay 73 4506.mp. (80)172 bay 73-4506.mp. (80)173 bay 734506.mp. (28)174 bay73 4506.mp. (1)175 bay734506.mp. (0)176 stivarga?.mp. (63)177 1019206-88-2.rn. (248)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

178 755037-03-7.rn. (412)179 everolimus/ (13298)180 everolimus.mp. (13570)181 affinitor?.mp. (24)182 afinitor?.mp. (427)183 certican?.mp. (521)184 "nvp rad 001".mp. (2)185 nvp rad001.mp. (1)186 "rad 001".mp. (1912)187 rad 001a.mp. (0)188 rad001.mp. (862)189 rad001a.mp. (0)190 sdz rad.mp. (90)191 votubia?.mp. (5)192 xience?.mp. (1430)193 zortress?.mp. (41)194 159351-69-6.rn. (9832)195 temsirolimus/ (5429)196 temsirolimus.mp. (5527)197 cci 779.mp. (1536)198 cci779.mp. (19)199 nsc 683864.mp. (10)200 nsc683864.mp. (0)201 rapamycin 2.mp. (80)202 rapamycin 42.mp. (3)203 torisel?.mp. (548)204 162635-04-3.mp. (0)205 343261-52-9.mp. (0)206 or/75-205 (334188)

Phase 3 phase 4 terms


207 phase 3 clinical trial/ (17852)208 phase 4 clinical trial/ (1571)209 "phase 3 clinical trial (topic)"/ (10675)210 "phase 4 clinical trial (topic)"/ (399)211 (phase adj3 three).mp. (8050)212 (phase adj3 iii).mp. (37410)213 (phase adj3 "3").mp. (42313)214 phase3.mp. (35)215 phaseiii.mp. (33)216 (phase adj3 "4").mp. (7559)217 (phase adj3 four).mp. (2525)218 (phase adj3 iv).mp. (2839)219 (phase adj3 "2/3").mp. (585)220 (phase adj3 "3/4").mp. (219)221 (phase adj3 "ii/iii").mp. (1648)222 (phase adj3 "iii/iv").mp. (86)223 (phase adj3 "two/three").mp. (16)224 (phase adj3 "three/four").mp. (2)225 or/207-224 (84997)

Combined results

226 74 and 206 and 225 (10755)227 limit 226 to embase (10466)228 limit 227 to yr="1990 -Current" (10459)229 limit 228 to (book or book series or conference abstract or conference paper or conference proceeding or "conference review" or editorial or erratum or letter or note or short survey or trade journal) (3992)230 228 not 229 (6467)231 exp animal/ (19088052)232 exp human/ (14854237)233 231 not (231 and 232) (4233815)234 230 not 233 (6448)* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

235 from 234 keep 1-5999 (5999)236 from 234 keep 6000-6448 (449)237 remove duplicates from 235 (5899)238 remove duplicates from 236 (449)239 237 or 238 (6348)

***************************

100 duplicates



For: Eitan Amir



Tel:

Fax:




Ovid EBM Reviews - Cochrane Central Register of Controlled Trials <May 2014>






416-946-6539

[email protected]








Database: EBM Reviews - Cochrane Central Register of Controlled Trials <May 2014>Search Strategy:--------------------------------------------------------------------------------1 neoplasm*.hw. (36713)2 exp Neoplasms/ (41333)3 cancer*.mp. (48256)4 tumor*.mp. (18164)5 tumour*.mp. (4029)6 carcin*.mp. (17253)7 neoplas*.mp. (37641)8 lymphoma*.mp. (4550)9 melanoma*.mp. (1783)10 melanotic*.mp. (11)11 metasta*.mp. (11966)12 non small cell.mp. (3840)13 nonsmall cell.mp. (121)14 (nonsmall adj2 cell).mp. (121)15 nsclc.mp. (2425)16 adenocarcin*.mp. (3245)17 osteosarcom*.mp. (222)18 phyllodes.mp. (2)19 cystosarcom*.mp. (5)20 fibroadenom*.mp. (60)21 hepatoma*.mp. (77)22 hepatoblastom*.mp. (25)23 plasmacytoma*.mp. (14)24 myeloma?.mp. (1803)25 blastoma*.mp. (8)26 lymphangioma*.mp. (7)


27 lymphangiomyoma*.mp. (1)28 lymphangiosarcoma*.mp. (1)29 lymphoblastoma*.mp. (5)30 lymphocytoma*.mp. (4)31 lymphosarcoma*.mp. (22)32 lymphoma?.mp. (4542)33 immunocytoma?.mp. (11)34 angiosarcoma*.mp. (5)35 malignan*.mp. (6765)36 astrocytoma*.mp. (234)37 neuroma?.mp. (95)38 cytoma?.mp. (1)39 gist.mp. (149)40 neurocytoma?.mp. (0)41 oncolog*.mp. (9035)42 exp Medical Oncology/ (142)43 exp Radiation Oncology/ (31)44 neoplasm staging/ (4442)45 staging.mp. (6181)46 squamous cell?.mp. (3296)47 cytosarcoma*.mp. (0)48 sarcoma*.mp. (904)49 hodgkin*.mp. (2986)50 non-hodgkin*.mp. (1727)51 nonhodgkin*.mp. (122)52 incidentaloma?.mp. (9)53 retinoblastoma?.mp. (33)54 plasmacytoma*.mp. (14)55 cholangiocarcinoma*.mp. (82)56 leiomyoblastoma*.mp. (1)57 leiomyocarcinoma*.mp. (0)


58 leiomyosarcoma*.mp. (51)59 sc.fs. ["secondary" floating subheading] (2466)60 melanosis.mp. (99)61 (hutchinson* adj2 freckle*).mp. (4)62 melanoameloblastom*.mp. (0)63 melanoblastom*.mp. (0)64 melanocarcin*.mp. (0)65 melanomalign*.mp. (0)66 naevocarcin*.mp. (1)67 nevocarcin*.mp. (0)68 adamantinom*.mp. (0)69 ameloblastom*.mp. (2)70 adenosquam*.mp. (54)71 teratoma*.mp. (47)72 leukemia*.mp. (5916)73 metaplas*.mp. (319)74 or/1-73 (86362)75 exp angiogenesis inhibitor/ (802)76 exp Protein Kinase Inhibitors/ (410)77 vasculotropin/ (536)78 bevacizumab.mp. (808)79 altuzan?.mp. (0)80 avastin?.mp. (88)81 nsc 704865.mp. (1)82 nsc704865.mp. (0)83 [216974-75-3.rn.] (0)84 aflibercept.mp. (26)85 "ave 0005".mp. (0)86 ave0005.mp. (0)87 eylea?.mp. (0)88 zaltrap?.mp. (1)


89 [845771-78-0.rn.] (0)90 [862111-32-8.rn.] (0)91 ramucirumab/ (0)92 ramucirumab.mp. (3)93 cyramza?.mp. (0)94 imc 1121 b.mp. (0)95 imc 1121b.mp. (1)96 imc1121b.mp. (0)97 ly 3009806.mp. (0)98 ly3009806.mp. (0)99 [947687-13-0.rn.] (0)100 sunitinib.mp. (164)101 pha 2909040ad.mp. (0)102 pha2909040ad.mp. (0)103 "su 010398".mp. (0)104 "su 011248".mp. (0)105 su 10398.mp. (0)106 su 11248.mp. (0)107 su010398.mp. (0)108 su011248.mp. (1)109 su10398.mp. (0)110 su11248.mp. (6)111 suo 11248.mp. (0)112 sutent?.mp. (1)113 suo11248.mp. (1)114 sorafenib.mp. (238)115 bay 43 9006.mp. (17)116 bay 439006.mp. (0)117 bay43 9006.mp. (0)118 bay439006.mp. (0)119 nexavar?.mp. (2)


120 [284461-73-0.rn.] (0)121 pazopanib.mp. (56)122 armala?.mp. (0)123 gw 786034.mp. (1)124 gw 786034b.mp. (0)125 gw 786034x.mp. (0)126 gw786034.mp. (3)127 gw786034b.mp. (0)128 gw786034x.mp. (0)129 sb 710468.mp. (0)130 sb 710468a.mp. (0)131 sb710468.mp. (0)132 sb710468a.mp. (0)133 votrient?.mp. (0)134 [444731-52-6.rn.] (0)135 [635702-64-6.rn.] (0)136 vandetanib.mp. (46)137 azd 6474.mp. (0)138 azd6474.mp. (0)139 caprelsa?.mp. (1)140 vandetinib.mp. (0)141 zactima?.mp. (4)142 zd 6474.mp. (0)143 zd6474.mp. (7)144 [338992-00-0.rn.] (0)145 [338992-48-6.rn.] (0)146 [443913-73-3.rn.] (0)147 cabozantinib.mp. (6)148 bms 907351.mp. (1)149 bms907351.mp. (0)150 cometriq?.mp. (0)


151 xl 184.mp. (0)152 xl184.mp. (4)153 [1140909-48-3.rn.] (0)154 [849217-68-1.rn.] (0)155 [942407-59-2.rn.] (0)156 axitinib.mp. (34)157 "ag 013736".mp. (8)158 ag 13736.mp. (1)159 ag013736.mp. (0)160 ag13736.mp. (0)161 inlyta?.mp. (0)162 [319460-85-0.rn.] (0)163 ponatinib/ (0)164 ponatinib.mp. (3)165 ap 24534.mp. (0)166 ap24534.mp. (1)167 iclusig?.mp. (0)168 [1114544-31-8.rn.] (0)169 [943319-70-8.rn.] (0)170 regorafenib.mp. (3)171 bay 73 4506.mp. (0)172 bay 73-4506.mp. (0)173 bay 734506.mp. (0)174 bay73 4506.mp. (0)175 bay734506.mp. (0)176 stivarga?.mp. (0)177 [1019206-88-2.rn.] (0)178 [755037-03-7.rn.] (0)179 everolimus/ (0)180 everolimus.mp. (505)181 affinitor?.mp. (0)


182 afinitor?.mp. (2)183 certican?.mp. (40)184 "nvp rad 001".mp. (0)185 nvp rad001.mp. (0)186 "rad 001".mp. (1)187 rad 001a.mp. (0)188 rad001.mp. (20)189 rad001a.mp. (0)190 sdz rad.mp. (5)191 votubia?.mp. (0)192 xience?.mp. (83)193 zortress?.mp. (0)194 [159351-69-6.rn.] (0)195 temsirolimus/ (0)196 temsirolimus.mp. (57)197 cci 779.mp. (13)198 cci779.mp. (0)199 nsc 683864.mp. (0)200 nsc683864.mp. (0)201 rapamycin 2.mp. (3)202 rapamycin 42.mp. (0)203 torisel?.mp. (4)204 162635-04-3.mp. (0)205 343261-52-9.mp. (0)206 or/75-205 (3056)207 phase 3 clinical trial/ (0)208 phase 4 clinical trial/ (0)209 "phase 3 clinical trial (topic)"/ (0)210 "phase 4 clinical trial (topic)"/ (0)211 (phase adj3 three).mp. (735)212 (phase adj3 iii).mp. (10099)


213 (phase adj3 "3").mp. (4153)214 phase3.mp. (0)215 phaseiii.mp. (4)216 (phase adj3 "4").mp. (1057)217 (phase adj3 four).mp. (383)218 (phase adj3 iv).mp. (478)219 (phase adj3 "2/3").mp. (119)220 (phase adj3 "3/4").mp. (44)221 (phase adj3 "ii/iii").mp. (362)222 (phase adj3 "iii/iv").mp. (19)223 (phase adj3 "two/three").mp. (7)224 (phase adj3 "three/four").mp. (4)225 or/207-224 (15572)226 74 and 206 and 225 (511)227 limit 226 to embase (89)228 limit 227 to yr="1990 -Current" (89)229 limit 228 to (book or book series or conference abstract or conference paper or conference proceeding or "conference review" or editorial or erratum or letter or note or short survey or trade journal) [Limit not valid; records were retained] (0)230 228 not 229 (89)231 exp animal/ (429940)232 exp human/ (429936)233 231 not (231 and 232) (4)234 230 not 233 (89)235 neoplasm*.hw. (36713)236 exp Neoplasms/ (41333)237 cancer*.mp. (48256)238 tumor*.mp. (18164)239 tumour*.mp. (4029)240 carcin*.mp. (17253)241 neoplas*.mp. (37641)242 lymphoma*.mp. (4550)


243 melanoma*.mp. (1783)244 melanotic*.mp. (11)245 metasta*.mp. (11966)246 non small cell.mp. (3840)247 nonsmall cell.mp. (121)248 (nonsmall adj2 cell).mp. (121)249 nsclc.mp. (2425)250 adenocarcin*.mp. (3245)251 osteosarcom*.mp. (222)252 phyllodes.mp. (2)253 cystosarcom*.mp. (5)254 fibroadenom*.mp. (60)255 hepatoma*.mp. (77)256 hepatoblastom*.mp. (25)257 plasmacytoma*.mp. (14)258 myeloma?.mp. (1803)259 blastoma*.mp. (8)260 lymphangioma*.mp. (7)261 lymphangiomyoma*.mp. (1)262 lymphangiosarcoma*.mp. (1)263 lymphoblastoma*.mp. (5)264 lymphocytoma*.mp. (4)265 lymphosarcoma*.mp. (22)266 lymphoma?.mp. (4542)267 immunocytoma?.mp. (11)268 angiosarcoma*.mp. (5)269 malignan*.mp. (6765)270 astrocytoma*.mp. (234)271 neuroma?.mp. (95)272 cytoma?.mp. (1)273 gist.mp. (149)


274 neurocytoma?.mp. (0)275 oncolog*.mp. (9035)276 exp Medical Oncology/ (142)277 exp Radiation Oncology/ (31)278 neoplasm staging/ (4442)279 staging.mp. (6181)280 squamous cell?.mp. (3296)281 cytosarcoma*.mp. (0)282 sarcoma*.mp. (904)283 hodgkin*.mp. (2986)284 non-hodgkin*.mp. (1727)285 nonhodgkin*.mp. (122)286 incidentaloma?.mp. (9)287 retinoblastoma?.mp. (33)288 plasmacytoma*.mp. (14)289 cholangiocarcinoma*.mp. (82)290 leiomyoblastoma*.mp. (1)291 leiomyocarcinoma*.mp. (0)292 leiomyosarcoma*.mp. (51)293 sc.fs. ["secondary" floating subheading] (2466)294 melanosis.mp. (99)295 (hutchinson* adj2 freckle*).mp. (4)296 melanoameloblastom*.mp. (0)297 melanoblastom*.mp. (0)298 melanocarcin*.mp. (0)299 melanomalign*.mp. (0)300 naevocarcin*.mp. (1)301 nevocarcin*.mp. (0)302 adamantinom*.mp. (0)303 ameloblastom*.mp. (2)304 adenosquam*.mp. (54)


305 teratoma*.mp. (47)306 leukemia*.mp. (5916)307 metaplas*.mp. (319)308 or/235-307 (86362)309 exp Angiogenesis Inhibitors/ (802)310 exp Neovascularization, Pathologic/ (522)311 limit 310 to yr="1990 - 1999" (97)312 exp Protein Kinase Inhibitors/ (410)313 exp Protein Kinases/ (1365)314 limit 313 to yr="1990 - 2004" (239)315 exp Vascular Endothelial Growth Factors/ (558)316 exp Endothelial Growth Factors/ (62)317 limit 316 to yr="1990 - 2003" (60)318 bevacizumab.mp. (808)319 altuzan?.mp. (0)320 avastin?.mp. (88)321 nsc 704865.mp. (1)322 nsc704865.mp. (0)323 [216974-75-3.rn.] (0)324 aflibercept.mp. (26)325 "ave 0005".mp. (0)326 ave0005.mp. (0)327 eylea?.mp. (0)328 zaltrap?.mp. (1)329 [845771-78-0.rn.] (0)330 [862111-32-8.rn.] (0)331 ramucirumab.mp. (3)332 cyramza?.mp. (0)333 imc 1121 b.mp. (0)334 imc 1121b.mp. (1)335 imc1121b.mp. (0)


336 ly 3009806.mp. (0)337 ly3009806.mp. (0)338 [947687-13-0.rn.] (0)339 sunitinib.mp. (164)340 pha 2909040ad.mp. (0)341 pha2909040ad.mp. (0)342 "su 010398".mp. (0)343 "su 011248".mp. (0)344 su 10398.mp. (0)345 su 11248.mp. (0)346 su010398.mp. (0)347 su011248.mp. (1)348 su10398.mp. (0)349 su11248.mp. (6)350 suo 11248.mp. (0)351 sutent?.mp. (1)352 suo11248.mp. (1)353 sorafenib.mp. (238)354 bay 43 9006.mp. (17)355 bay 439006.mp. (0)356 bay43 9006.mp. (0)357 bay439006.mp. (0)358 nexavar?.mp. (2)359 [284461-73-0.rn.] (0)360 pazopanib.mp. (56)361 armala?.mp. (0)362 gw 786034.mp. (1)363 gw 786034b.mp. (0)364 gw 786034x.mp. (0)365 gw786034.mp. (3)366 gw786034b.mp. (0)


367 gw786034x.mp. (0)368 sb 710468.mp. (0)369 sb 710468a.mp. (0)370 sb710468.mp. (0)371 sb710468a.mp. (0)372 votrient?.mp. (0)373 [444731-52-6.rn.] (0)374 [635702-64-6.rn.] (0)375 vandetanib.mp. (46)376 azd 6474.mp. (0)377 azd6474.mp. (0)378 caprelsa?.mp. (1)379 vandetinib.mp. (0)380 zactima?.mp. (4)381 zd 6474.mp. (0)382 zd6474.mp. (7)383 [338992-00-0.rn.] (0)384 [338992-48-6.rn.] (0)385 [443913-73-3.rn.] (0)386 cabozantinib.mp. (6)387 bms 907351.mp. (1)388 bms907351.mp. (0)389 cometriq?.mp. (0)390 xl 184.mp. (0)391 xl184.mp. (4)392 [1140909-48-3.rn.] (0)393 [849217-68-1.rn.] (0)394 [942407-59-2.rn.] (0)395 axitinib.mp. (34)396 "ag 013736".mp. (8)397 ag 13736.mp. (1)


398 ag013736.mp. (0)399 ag13736.mp. (0)400 inlyta?.mp. (0)401 [319460-85-0.rn.] (0)402 ponatinib.mp. (3)403 ap 24534.mp. (0)404 ap24534.mp. (1)405 iclusig?.mp. (0)406 [1114544-31-8.rn.] (0)407 [943319-70-8.rn.] (0)408 regorafenib.mp. (3)409 bay 73 4506.mp. (0)410 bay 73-4506.mp. (0)411 bay 734506.mp. (0)412 bay73 4506.mp. (0)413 bay734506.mp. (0)414 stivarga?.mp. (0)415 [1019206-88-2.rn.] (0)416 [755037-03-7.rn.] (0)417 everolimus.mp. (505)418 affinitor?.mp. (0)419 afinitor?.mp. (2)420 certican?.mp. (40)421 "nvp rad 001".mp. (0)422 nvp rad001.mp. (0)423 "rad 001".mp. (1)424 rad 001a.mp. (0)425 rad001.mp. (20)426 rad001a.mp. (0)427 sdz rad.mp. (5)428 votubia?.mp. (0)


429 xience?.mp. (83)430 zortress?.mp. (0)431 [159351-69-6.rn.] (0)432 temsirolimus.mp. (57)433 cci 779.mp. (13)434 cci779.mp. (0)435 nsc 683864.mp. (0)436 nsc683864.mp. (0)437 rapamycin 2.mp. (3)438 rapamycin 42.mp. (0)439 torisel?.mp. (4)440 162635-04-3.mp. (0)441 343261-52-9.mp. (0)442 309 or 311 or 312 or 314 or 315 or 317 (1884)443 or/318-441 (1823)444 442 or 443 (3395)445 clinical trial, phase iii/ (0)446 Clinical Trials, Phase III as Topic/ (135)447 (phase adj3 three).mp. (735)448 (phase adj3 iii).mp. (10099)449 (phase adj3 "3").mp. (4153)450 phase3.mp. (0)451 phaseiii.mp. (4)452 clinical trial, phase iv/ (0)453 CLINICAL TRIALS, PHASE IV AS TOPIC/ (4)454 (phase adj3 "4").mp. (1057)455 (phase adj3 four).mp. (383)456 (phase adj3 iv).mp. (478)457 (phase adj3 "2/3").mp. (119)458 (phase adj3 "3/4").mp. (44)459 (phase adj3 "ii/iii").mp. (362)


460 (phase adj3 "iii/iv").mp. (19)461 (phase adj3 "two/three").mp. (7)462 (phase adj3 "three/four").mp. (4)463 or/445-462 (15572)464 exp Clinical Trial/ (114)465 limit 464 to yr="1990 - 1992" (1)466 exp clinical trial as topic/ (40126)467 limit 466 to yr="1990 - 1992" (2784)468 463 or 465 or 467 (18315)469 308 and 444 and 468 (530)470 Animals/ (7569)471 Humans/ (429936)472 470 not (470 and 471) (1)473 469 not 472 (530)474 limit 473 to yr="1990 -Current" (530)475 remove duplicates from 474 (519)476 230 or 475 (523)

***************************

11 duplicates****************************************************************************************************************************************************************************************************************************


Appendix 2: Baseline characteristics of patients in the studies included in the systematic review

First author and year Malignancy Adjuvan

t

Concurrent anthracyclines

Blinded

Mean/ median follow-up Arm

Number in safety analysis

Mean/ median age

Female %

Ramlau 2012 Non-small cell lung cancer N N Y 5 monthsAflibercept 456 59.6 33.1

Placebo 457 59.6 34.4

Rougier 2013 Pancreatic N N Y 13 weeksAflibercept 270 62 41

Placebo 271 61 43

Tannock 2013 Prostate N N Y 24 monthsAflibercept 611 68 0

Placebo 598 68 0

Van custem 2012 Colorectal N N Y 20 weeksAflibercept 611 61 40.4

Placebo 605 61 42.5

Cunningham 2013 Colorectal N N N 32 monthsBevacuzimab 134 NA 40

Placebo 136 NA 40

Tebbutt 2010 Colorectal N N N 31 monthsBevacuzimab 157 67 35

Placebo 156 69 37

Aghajanian 2012 Gynecological N N Y 10 monthsBevacuzimab 247 60 100

Placebo 233 61 100

Allegra 2011 Colorectal Y N N 28.5 monthsBevacuzimab 1354 NA 50.2

Placebo 1356 NA 50.2

Bear 2012 Breast Y Y N

NA (Follow-up for LV dysfunction 18 months after last

dose)

Bevacuzimab 595 NA 100

Placebo 596 NA 100

Boutsikou 2013 Non-small cell lung cancer N N N 440 daysBevacuzimab 56 62.5 20

Erlotinib 61 65 15

Brufsky 2011 Breast N N N 5 monthsBevacuzimab 458 55 100

Placebo 221 55 100

Burger 2011 Gynecological N N Y 12 monthsBevacuzimab 618 60 100

Placebo 621 60 100

Cameron 2013 Breast Y Y N 32 monthsBevacuzimab 1288 NA 100

Placebo 1271 NA 100

Chinot 2014 Glioblastoma N N Y 10 monthsBevacuzimab 465 57 38.4

Placebo 446 56 35.6

Corrie 2014 Melanoma Y N N 25 monthsBevacuzimab 671 56 44

Placebo 672 55 44

De Gramont 2012 Colorectal Y N N 5 monthsBevacuzimab 1145 58 43

Placebo 1126 58 49

Escudier 2007, a Renal Cell N N N 7 monthsBevacuzimab 337 61 32

Placebo 304 60 27

Gianni 2013 Breast N N N 12 monthsBevacuzimab 215 53 100

Placebo 206 55 100


Guan2011 Colorectal N N N 5 monthsBevacuzimab 141 53 49.6

Placebo 70 50 44.8

Herbst 2011 Non-small cell lung cancer N N N 127 daysBevacuzimab 313 64.8 46

Placebo 313 65 46

Hurwitz 2004 Colorectal N N N 34 monthsBevacuzimab 393 59.5 41

Placebo 397 59.2 40

Hurwitz 2005 Colorectal N N N 8 monthsBevacuzimab 109 59.7 37.3

Placebo 98 60.3 37

Kelly 2012 Prostate N N Y 9 monthsBevacuzimab 504 68.8 0

Placebo 505 69.3 0

Kindler 2010 Colorectal N N Y 3 monthsBevacuzimab 300 63.7 42

Placebo 302 65 49

Miles 2010 Breast N N Y 7 monthsBevacuzimab 499 55 100

Placebo 231 55 100

Miller 2005 Breast N N N 5 monthsBevacuzimab 229 51 100

Placebo 215 52 100

Miller 2007 Breast N N N 9 monthsBevacuzimab 365 56 100

Placebo 346 55 100

Ohtsu 2011 Gastric N N Y 6 monthsBevacuzimab 386 58 34

Placebo 381 59 33

Perren 2011 Gynecological N N N 18 monthsBevacuzimab 745 57 100

Placebo 753 57 100

Pujade-Loraine 2014 Gynecological N Y N 5 months

Bevacuzimab 179 62 100

Placebo 181 61 100

Reck 2009 Non-small cell lung cancer N Y Y 4 monthsBevacuzimab 659 58 37

Placebo 327 59 36

Rini 2010 Renal Cell N N N 9 monthsBevacuzimab 362 61 27

Placebo 347 62 34

Robert 2011, a Breast N N Y 8 monthsBevacuzimab 404 56 100

Placebo 201 57 100

Robert 2011, b Breast N N Y

9 months

Bevacuzimab 203 55 100

Placebo 102 55 100

Robert 2011, c Breast Y Y YBevacuzimab 210 55 100

Placebo 100 55 100

Saltz 2008 Colorectal N N Y 183 daysBevacuzimab 694 60 40

Placebo 675 60 44

Sandler 2006 Non-small cell lung cancer N N N 5 monthsBevacuzimab 427 NA 50

Placebo 440 NA 42

Shen 2015 Gastric N N Y 5 monthsBevacuzimab 100 54.2 32

Placebo 101 55.5 27.5

Stathopoulos 2010 Colorectal N Y N 24 months Bevacuzimab 114 67 36


Placebo 108 62 37

Tewari 2014 Cervical N N N 7 monthsBevacuzimab 220 48 100

Placebo 219 47 100

Van Custem 2009 Pancreatic N N Y 6 monthsBevacuzimab 296 62 43

Placebo 287 61 38

Giantonio 2007 Colorectal N N N 5 monthsBevacuzimab 287 62 39.5

Placebo 285 61 39.2

Von Mincwitz 2012 Breast Y Y N NABevacuzimab 956 49 100

Placebo 969 48 100

Stintzing 2012 Colorectal N N N 5 monthsBevacuzimab 46 63 35

Cetuximab 50 65 36

Gilbert 2014 Glioblastoma N N Y 9 monthsBevacuzimab 303 58 43

Placebo 300 58 37

Kader 2013 Breast N N N 10 monthsBevacuzimab 20 51 100

Placebo 21 52 100

Elisei 2013 Thyroid N N Y 171 daysCabozantinib 214 55 31.1

Placebo 109 55 36.9

Sternberg 2013 Renal Cell N N Y 6 monthsPazopanib 290 59 32

Placebo 145 60 25

Van der graaf 2012 sarcoma N N Y 14 weeksPazopanib 239 56.7 60

Placebo 123 51.9 56

Fuchs 2014 Gastric N N Y 7 weeksPlacebo 115 60 32

Ramucirumab 236 60 29

Garon 2014 Non-small cell lung cancer N N Y 14 weeksPlacebo 618 61 34

Ramucirumab 627 62 33

Grothey 2013 Colorectal N N Y 2 monthsPlacebo 253 61 40

Regorafenib 500 61 38

Kindler 2011 Pancreatic N N Y 3 monthsAxtinib 305 61 39

Placebo 308 62 41

Brose 2014 Thyroid N N Y 9 monthsPlacebo 209 63 55

Sorafenib 207 63 50

Cheng 2009 Hepatic cell N N Y 2 monthsPlacebo 75 52 13

Sorafenib 149 51 15

Escudier 2009 Renal Cell N N Y 4 monthsPlacebo 451 59 25

Sorafenib 452 58 30

Flaherty 2013 Melanoma N N Y 5 monthsPlacebo 397 59 39

Sorafenib 393 61 34

Goncalves 2012 Pancreatic N N Y 5 monthsPlacebo 52 64 38

Sorafenib 50 61 42

Hauschild 2009 Melanoma N N Y 17 weeks Placebo 134 56 36


Sorafenib 134 57 38

Kudo 2011 Hepatic cell N N Y 19 weeksPlacebo 227 70 27

Sorafenib 229 69 24

llovet 2008 Hepatic cell N N Y 5 monthsPlacebo 302 66 13

Sorafenib 297 65 13

Paz-Ares 2011 Non-small cell lung cancer N N Y 18 weeksPlacebo 384 58 37

Sorafenib 385 60 41

Scagliotti 2010 Non-small cell lung cancer N N Y 17 weeksPlacebo 459 63 38

Sorafenib 463 62 37

Motzer 2007 Renal Cell N N N 5 monthsIFN alpha 360 59 28

Sunitinib 375 62 29

Barrios 2010 Breast N N N 61 dayscepecitabine 240 53 100

Sunitinib 238 53 100

Bergh 2012 Breast N N N 22 weeksPlacebo 293 56 100


Carrato 2013 Colorectal N N Y 8 monthsPlacebo 379 58 47

Sunitinib 384 59 42

Crown 2013 Breast N N N 6 monthsPlacebo 215 54 100


Demetri 2006 Gastrointestinal stromal N N Y 47 daysPlacebo 102 55 39

Sunitinib 202 58 36

Michaelson 2014 Prostate N N Y 98 daysPlacebo 285 68 0

Sunitinib 581 69 0

Raymond 2011 Neuroendocrine pancreatic N N Y 4 monthsPlacebo 82 57 53

Sunitinib 83 56 51

Scagliotti 2012 Non-small cell lung cancer N N Y 132 daysPlacebo 477 61 41

Sunitinib 473 61 38

Hecht 2011 Colorectal N N Y 7 monthsPlacebo 574 60 40

Vatalanib 579 59 37

Van Custem 2011 Colorectal N N Y 4 monthsPlacebo 420 59 37.5

Vatalanib 422 61 38

De Boer 2011 Non-small cell lung cancer N N Y 94 monthsPlacebo 273 60 38

Vandetanib 260 60 38

Herbst 2010 Non-small cell lung cancer N N Y 13 weeksPlacebo 690 59 32


Lee 2012 Non-small cell lung cancer N N Y 13 weeksPlacebo 303 60 52


Natale 2011 Non-small cell lung cancer N N Y 9 weeksErlotinib 614 61 36


Wells 2012 Thyroid N N Y 65 weeksPlacebo 99 53 44



********************************************************************************************************************************************************************************************************


Appendix 3: Table illustrating the results of the risk of bias assessment for the studies included in the systematic review and meta-analysis. A green box indicates a low risk of

bias, yellow indicates unclear risk, and red indicates high risk.

# Author, year Randomization Allocation concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

1 Ramlau 2012

2 Rougier 2013

3 Tannock 2013

4 Van custem 2012

5 Cunningham 2013

6 Tebbutt 2010

7 Aghajanian 2012

8 Allegra 2009

9 Bear 2012

10 Boutsikou 2013

11 Brufsky 2011

12 Burger 2011

13 Cameron 2013

14 Chinot 2014

15 Corrie 2014

16 De Gramont 2012

17 Escudier 2007, a

18 Gianni 2013

19 Guan2011

20 Herbst 2011

21 Hurwitz 2004

22 Hurwitz 2005

23 Kelly 2012

24 Kindler 2010

25 Miles 2010

26 Miller 2005

27 Miller 2007

28 Ohtsu 2011

29 Perren 2011

30Pujade-Loraine 2014

31 Reck 2009

32 Rini 2010

33 Robert 2011, a

34 Saltz 2008* Library staff make every effort to provide accurate and complete database search results. However, we assume no liability for information retrieved, its interpretation, applications or omissions.

35 Sandler 2006

36 Shen 2015

37 Stathopoulos 2010

38 Tewari 2014

39 Van Custem 2009

40 Giantonio 2007

41 Von Mincwitz 2012

42 Stintzing 2012

43 Gilbert 2014

44 Kader 2013

45 Elisei 2013

46 Sternberg 2010

47 Van der graaf 2012

48 Fuchs 2014

49 Garon 2014

50 Grothey 2013

51 Kindler 2011

52 Brose 2014

53 Cheng 2009

54 Escudier 2009

55 Flaherty 2013

56 Goncalves 2012

57 Hauschild 2009

58 Kudo 2011

59 llovet 2008

60 Paz-Ares 2011

61 Scagliotti 2010

62 Motzer 2007

63 Barrios 2010

64 Bergh 2012

65 Carrato 2013

66 Crown 2013

67 Demetri 2006

68 Michaelson 2014

69 Raymond 2011

70 Scagliotti 2012

71 Hecht 2011

72 Van Custem 2011

73 De Boer 2011


74 Herbst 2010

75 Lee 2012

76 Natale 2011

77 Wells 2012


******************************************************************************************************************************************************


Appendix 4: Forest plots demonstrating main analysis of risk of adverse cardiovascular events with angiogenesis inhibitor containing regimens compared with regimens that do

not contain them

Hypertension


Severe Hypertension


Arterial thromboembolism

Cardiac Dysfunction


Congestive Heart Failure


Cardiac Ischemia

Fatal CV events


DVT


Pulmonary embolism

Unspecified venous thromboembolism


Unspecified thromboembolism


Appendix 5: Forest plots demonstrating results of subgroup analyses

Direct VEGF inhibitors versus small molecule agents – hypertension


Direct VEGF inhibitors versus small molecule agents – Severe hypertension


Direct VEGF inhibitors versus small molecule agents – Arterial thromboembolism


Direct VEGF inhibitors versus small molecule agents – Cardiac dysfunction

Direct VEGF inhibitors versus small molecule agents – Congestive heart failure


Direct VEGF inhibitors versus small molecule agents – Cardiac ischemia


Direct VEGF inhibitors versus small molecule agents – Fatal CV events


Direct VEGF inhibitors versus small molecule agents – Deep Vein thrombosis


Direct VEGF inhibitors versus small molecule agents - Pulmonary Embolism


Direct VEGF inhibitors versus small molecule agents – Unspecified Venous thromboembolism


Direct VEGF inhibitors versus small molecule agents – Unspecified thromboembolism

Metastatic versus adjuvant– hypertension


Metastatic versus adjuvant– Severe hypertension


Metastatic versus adjuvant– Arterial thromboembolism


Metastatic versus adjuvant– Cardiac dysfunction

Metastatic versus adjuvant – Congestive heart failure


Metastatic versus adjuvant– Cardiac ischemia


Metastatic versus adjuvant– Fatal CV events


Metastatic versus adjuvant– Deep Vein thrombosis


Metastatic versus adjuvant- Pulmonary Embolism


Metastatic versus adjuvant– Unspecified Venous thromboembolism


Metastatic versus adjuvant– Unspecified thromboembolism

Blinded – hypertension


Blinded – Severe hypertension


Blinded – Arterial thromboembolism


Blinded – Cardiac dysfunction

Blinded – Congestive heart failure


Blinded – Cardiac ischemia


Blinded – Fatal CV events


Blinded – Deep Vein thrombosis


Blinded - Pulmonary Embolism


Blinded – Unspecified Venous thromboembolism


Blinded – Unspecified thromboembolism

Anthracycline – hypertension


Anthracycline – Severe hypertension


Anthracycline – Cardiac dysfunction

Anthracycline – Congestive heart failure


Anthracycline – Fatal CV events


**********************************************************************************************************************************************


Appendix 6: Summary of statistics from the subgroup and meta-regression analyses

Test for subgroup difference between direct ligand vs. small molecules

Sub-group interaction by adjuvant versus metastatic setting

Sub-group interaction by blinded versus unblinded studies

Beta-coefficient for age (p-value)

Chi² = 0.22, df = 1 (P = 0.64) Chi² = 4.86, df = 1 (P = 0.03) Chi² = 2.47, df = 1 (P = 0.12) -0.41 (p-value 0.033)Chi² = 3.93, df = 1 (P = 0.05) Chi² = 8.24, df = 1 (P = 0.004) Chi² = 7.47, df = 1 (P = 0.006) -0.49 (p-value 0.21)NA (no included studies with small molecule agents) Chi² = 0.00, df = 1 (P = 0.99) Chi² = 1.17, df = 1 (P = 0.28) 0.06 (p-value 0.66)Chi² = 1.85, df = 1 (P = 0.17) Chi² = 1.48, df = 1 (P = 0.22) Chi² = 0.01, df = 1 (P = 0.93) -0.08 (p-value 0.38)NA (no events reported in included studies of small molecule agents) Chi² = 0.55, df = 1 (P = 0.46) Chi² = 0.02, df = 1 (P = 0.87) -0.29 (p-value 0.004)Chi² = 0.50, df = 1 (P = 0.48) Chi² = 2.41, df = 1 (P = 0.12) Chi² = 1.84, df = 1 (P = 0.18) -0.07 (p-value 0.76)Chi² = 0.00, df = 1 (P = 0.97) Chi² = 0.11, df = 1 (P = 0.74) Chi² = 0.16, df = 1 (P = 0.69) -0.19 (p-value 0.18)

Chi² = 1.70, df = 1 (P = 0.19) NA (no included studies with small molecule agents) Chi² = 1.70, df = 1 (P = 0.19) 0.07 (p-value 0.72)

Chi² = 0.46, df = 1 (P = 0.50) NA (no included studies with small molecule agents) Chi² = 0.28, df = 1 (P = 0.60) 0.07 (p-value 0.43)

Unspecified venous thromboembolism Chi² = 5.13, df = 1 (P = 0.02) Chi² = 9.79, df = 1 (P = 0.002) Chi² = 11.49, df = 1 (P = 0.0007) -0.04 (p-value 0.15)Unspecified thromboembolism Chi² = 1.67, df = 1 (P = 0.20) Chi² = 2.25, df = 1 (P = 0.13) Chi² = 8.35, df = 1 (P = 0.004) -0.10 (p-value 0.047)


€¦ · web view* library staff make every effort to provide accurate and complete database...

Documents